Beatriz Tavira1, Juan Gómez1, Carmen Díaz-Corte2, Laura Llobet3, Eduardo Ruiz-Pesini3, Francisco Ortega4, Eliecer Coto5. 1. Genética Molecular, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain. 2. Nefrología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain. 3. Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Centro de Investigaciones Biomédicas En Red de Enfermedades Raras (CIBERER), Universidad de Zaragoza, Zaragoza, Spain. 4. Nefrología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; Fundación Renal I. Alvarez de Toledo, Madrid, Spain. 5. Genética Molecular, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; Fundación Renal I. Alvarez de Toledo, Madrid, Spain; Universidad de Oviedo, Oviedo, Spain. Electronic address: eliecer.coto@sespa.princast.es.
Abstract
BACKGROUND AND AIMS: Tacrolimus (Tac) is an immunosuppressive drug widely used to avoid organ rejection. New-onset diabetes after transplantation (NODAT) is a major complication among transplanted patients who receive Tac. The increased risk for NODAT could be partly mediated by the effect of Tac on mitochondria from pancreatic beta-cells. Common and rare mitochondrial DNA variants have been linked to the risk of diabetes. Our aim was to determine whether mtDNA polymorphisms/haplogroups were associated with NODAT in Tac-treated kidney transplanted. METHODS: Seven polymorphisms that define the common European haplogroups were determined in 115 NODAT and 197 no-NODAT patients. RESULTS: Haplogroup H was significantly more frequent in the NODAT group (50% vs. 35%; p=0.01, OR=1.82). There was no difference between patients without and with (n=106) D2M prior to the transplant. CONCLUSIONS: Mitochondrial haplogroup H was associated with the risk for NODAT among Tac-treated transplanted patients. The reported differences between the mtDNA variants could explain the increased NODAT-risk among H-patients.
BACKGROUND AND AIMS: Tacrolimus (Tac) is an immunosuppressive drug widely used to avoid organ rejection. New-onset diabetes after transplantation (NODAT) is a major complication among transplanted patients who receive Tac. The increased risk for NODAT could be partly mediated by the effect of Tac on mitochondria from pancreatic beta-cells. Common and rare mitochondrial DNA variants have been linked to the risk of diabetes. Our aim was to determine whether mtDNA polymorphisms/haplogroups were associated with NODAT in Tac-treated kidney transplanted. METHODS: Seven polymorphisms that define the common European haplogroups were determined in 115 NODAT and 197 no-NODAT patients. RESULTS: Haplogroup H was significantly more frequent in the NODAT group (50% vs. 35%; p=0.01, OR=1.82). There was no difference between patients without and with (n=106) D2M prior to the transplant. CONCLUSIONS: Mitochondrial haplogroup H was associated with the risk for NODAT among Tac-treated transplanted patients. The reported differences between the mtDNA variants could explain the increased NODAT-risk among H-patients.
Authors: Wesley Hayes; Sheila Boyle; Adrian Carroll; Detlef Bockenhauer; Stephen D Marks Journal: Pediatr Nephrol Date: 2016-12-30 Impact factor: 3.714
Authors: Nigel S Kanagasundaram; Simon V Baudouin; Sarah Rowling; Mahesh Prabhu; John H Dark; Timothy H J Goodship; Patrick F Chinnery; Gavin Hudson Journal: Sci Rep Date: 2019-02-19 Impact factor: 4.379
Authors: Yael Peled; Eilon Ram; Jacob Lavee; Alexander Tenenbaum; Enrique Z Fisman; Dov Freimark; Robert Klempfner; Leonid Sternik; Michael Shechter Journal: Cardiovasc Diabetol Date: 2019-10-11 Impact factor: 9.951
Authors: María Angeles Jiménez-Sousa; Eduardo Tamayo; María Guzmán-Fulgencio; Amanda Fernández-Rodríguez; María Heredia-Rodriguez; Mónica García-Álvarez; Jesús F Bermejo-Martin; Daniel Pineda-Tenor; Patricia Ruiz-Granado; Elisa Alvarez-Fuente; Esther Gómez-Sanchez; José I Gómez-Herreras; Salvador Resino Journal: Int J Med Sci Date: 2014-08-17 Impact factor: 3.738